Clinical features
| NP definite | NP probable | |
|---|---|---|
| MRC, Medical Research Council; NP, neurophysiologically; ODSS, Overall Disability Sum Score. | ||
| n (%) | 27 (54) | 23 (46) |
| Patients who responded to treatment, n (%) | 20 (74) | 17 (73.9) |
| Male/female | 13/14 | 18/5 |
| Mean (range) age at assessment, years | 54.2 (14–81) | 53.7 (17–76) |
| Mean (SD) duration of disease, years | 7.7 (6.8) | 9.89 (9) |
| Mean (SD) MRC score at initiation of treatment | 57.8 (10) | 53.7 (14) |
| Mean (SD) ODSS score at initiation of treatment | 6.3 (1.8) | 6.1 (2.9) |
| Symmetrical sensorimotor phenotype, n (%) | 16 (59.3) | 14 (60.9) |
| ASSM phenotype, n (%) | 3 (11.1) | 5 (21.7) |
| DSSM phenotype, n (%) | 5 (18.5) | 4 (17.4) |
| Symmetrical motor phenotype, n (%) | 1 (3.7) | 0 |
| Symmetrical sensory phenotype, n (%) | 2 (7.4) | 0 |
| Patients who had CSF analysis, n (%) | 24 (88.9) | 18 (78.3) |
| Patients with CSF protein>400 mg/l, n (%) | 19 (79.2) | 16 (88.9) |
| Patients who had nerve biopsy, n (%) | 16 (59.3) | 11 (47.8) |
| Patients who had pathological lymphocytic endoneurial infiltrates, n | 5 | 0 |
| Patients who had pathological numbers of demyelinated/remyelinated fibres, n | 7 | 6 |